Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia

We report long-term follow-up from the RESONATE-2 phase 3 study of the once-daily Bruton's tyrosine kinase inhibitor ibrutinib, which is the only targeted therapy with significant progression-free survival (PFS) and overall survival (OS) benefit in multiple randomized chronic lymphocytic leukem...

Full description

Bibliographic Details

Published in:	Blood advances Vol. 6; no. 11; pp. 3440 - 3450
Main Authors:	Barr, Paul M., Owen, Carolyn, Robak, Tadeusz, Tedeschi, Alessandra, Bairey, Osnat, Burger, Jan A., Hillmen, Peter, Coutre, Steve E., Dearden, Claire, Grosicki, Sebastian, McCarthy, Helen, Li, Jian-Yong, Offner, Fritz, Moreno, Carol, Zhou, Cathy, Hsu, Emily, Szoke, Anita, Kipps, Thomas J., Ghia, Paolo
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 14.06.2022 American Society of Hematology
Subjects:	Adenine - analogs & derivatives Chlorambucil - adverse effects Clinical Trials and Observations Follow-Up Studies Humans Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Leukemia, Lymphocytic, Chronic, B-Cell - genetics Piperidines Pyrazoles - adverse effects Pyrimidines - adverse effects Treatment Outcome
ISSN:	2473-9529, 2473-9537, 2473-9537
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!